INM.US InMed Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
15.56 USD
Close of Nov 15, 2026
5.75 23.30
Market cap
USD 8.55M
P/E
-
P/B
8.59x
ROE
-
Dividend yield
5,049.73%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is INM.US undervalued?

Graham number

The Graham number of InMed Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

InMed Pharmaceuticals Inc fundamental analysis

No fundamental analysis for InMed Pharmaceuticals Inc yet.

InMed Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About InMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceutical…

Full company profile